Intracranial Stents Global Market Report 2024

Intracranial stents are tubular devices placed inside blood vessels, canals, or ducts, primarily used for treating intracranial stenosis and brain aneurysms by opening blocked arteries.

The primary types of intracranial stents include self-expanding stents, balloon-expanding stents, and stent-assisted coil embolization. Self-expanding stents expand autonomously after insertion into the intended lumen, such as a blood vessel or organ. Balloon-expanding stents, also known as balloon-expandable stents, offer higher radial stiffness and more precise placement, designed to address restenosis in the iliac artery by opening clogged arteries and restoring blood flow. Stent-assisted coil embolization plays a role in stabilizing coils within an aneurysm, providing support for coil deposition while preventing coil herniation into the parent vessel lumen. These intracranial stents are applied in the treatment of conditions such as brain aneurysms and intracranial stenosis, and find utilization in various sectors including hospitals, ambulatory surgery centers, and others.

The intracranial stents market research report is one of a series of new reports that provides intracranial stents market statistics, including intracranial stents industry, intracranial stents global market size, regional shares, competitors with intracranial stents market share, detailed intracranial stents market segments, market trends and opportunities, and any further data you may need to thrive in the intracranial stents industry. This intracranial stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intracranial stents market size has grown rapidly in recent years. It will grow from $0.42 billion in 2023 to $0.49 billion in 2024 at a compound annual growth rate (CAGR) of 15.8%. The growth observed in the historical period can be attributed to factors such as increased awareness of stroke risks, improved patient education, a rise in radiation safety measures, an increased aging population, and the emergence of minimally invasive techniques.

The intracranial stents market size is expected to see rapid growth in the next few years. It will grow to $0.87 billion in 2028 at a compound annual growth rate (CAGR) of 15.5%. The projected growth in the forecast period can be linked to the expansion of telehealth services, the adoption of genomic medicine, the rising healthcare infrastructure, the expansion of stroke rehabilitation services, and increasing health initiatives. Key trends expected in the forecast period involve the adoption of bioresorbable intracranial stents, the adoption of neurointerventional robotics, the integration of advanced imaging technologies, the adoption of pediatric intracranial stents, and the development of dual antiplatelet therapy strategies.

The anticipated rise in the incidence of brain aneurysms is poised to drive the growth of the intracranial stents market in the coming years. Characterized by the development of a bulge in the blood vessels of the brain, a brain aneurysm poses the risk of rupture, leading to brain hemorrhage and potential fatality. Intracranial vessel stenting (IVS) emerges as a minimally invasive treatment for addressing serious cerebral artery stenosis, a condition involving the weakening of arteries delivering blood to the brain. Reports indicate that approximately 3.2% of individuals worldwide have unruptured aneurysms, underscoring the significance of the increasing incidence of brain aneurysms in driving the growth of the intracranial stents market.

The surge in medical imaging tests is expected to propel the growth of the intracranial stents market. Medical imaging tests, also known as diagnostic imaging tests, constitute a set of techniques employed by healthcare professionals to create visual representations of the interior of the human body. Intracranial stents play a crucial role in endovascular treatment for cerebrovascular conditions, providing structural support, enhancing blood flow, and preventing complications. Medical imaging tests are instrumental in diagnosing, guiding, and assessing these procedures, ensuring the accurate and effective placement of intracranial stents. With 43.3 million imaging tests recorded in England between April 2021 and March 2022, the increasing reliance on medical imaging tests contributes significantly to the growth of the intracranial stents market.

Major companies in the intracranial stents market are actively innovating, exemplified by the introduction of new products like the Onyx Frontier drug-eluting stent (DES) by Medtronic plc. Launched in August 2022, the Onyx Frontier DES is designed to treat coronary artery disease (CAD) caused by plaque accumulation in coronary arteries. Its architecture makes it suitable for sophisticated percutaneous cardiac intervention (PCI) with superior deliverability. Another notable innovation is the Pegasus HPC stent system, introduced by Wallaby Medical LLC in September 2022. This medical device is utilized for endovascular repair of the neck and intracranial arteries in patients with intracranial aneurysms and stenoses in intracranial atherosclerotic disease (ICAD).

In January 2021, the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institute under the Department of Science & Technology (DST) in India, announced Technology Transfer Agreements with Biorad Medisys. This collaboration involves the transfer of technology for two biomedical implant devices - an Atrial Septal Defect Occluder and an Intracranial Flow Diverter Stents. Developed in collaboration with the National Aerospace Laboratories, Bangalore (CSIR-NAL), these devices utilize superelastic NiTiNOL alloys and offer innovative solutions in the field. Biorad Medisys, an India-based company specializing in manufacturing various implants and surgical devices, is a key player in this collaborative effort.

Major companies operating in the intracranial stents market include Medtronic PLC, Balt Extrusion LLC., Stryker Corporation, MicroPort Scientific Corporation, Boston Scientific Corporation, Acandis GmbH, Admedes Schuessler GmbH, MicroVention Inc., Phenox GmbH, Terumo Corporation, Johnson & Johnson Services Inc., Abbott Laboratories, Brainlab AG, Cardiatis SA, Cook Medical LLC, DePuy Synthes, Endologix Inc., InspireMD Inc., Integra LifeSciences Corporation, Kaneka Corporation, Kerecis Limited, Penumbra Inc., Rapid Medical Ltd., Vascular Solutions Inc., W. L. Gore & Associates Inc., Biotronik SE & Co. KG, Cardionovum GmbH, Codman Neuro, C.R. Bard Inc., Cerebral Stents.

North America was the largest region in the intracranial stents market in 2023. Asia-Pacific is expected to be the fastest region in the intracranial stents market share during the forecast period. The regions covered in the intracranial stents market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the intracranial stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

The intracranial stents market consists of sales of Neuroform stents, Solitaire, Enterprise, and Leo plus, and Wingspan stent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.